Patents
Literature
20 results about "Mumpsvax" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Mumpsvax is a mumps vaccine made of mumps virus. Mumpsvax is a product of Merck & Co.,Inc. The vaccine is a component of Merck's three-virus MMR vaccine. Mumpsvax is administered by a subcutaneous injection of live virus reconstituted from freeze-dried vaccine. The dosage of the mumps vaccine component in MMR is the same as of Mumpsvax, "Each 0.5 mL dose contains not less than 20,000 TCID₅₀ of mumps virus." The Merck product information recommends MMR as the secondary vaccination treatment with Mumpsvax. Mumpsvax is produced from the Jeryl Lynn strain of mumps virus developed by Maurice Hilleman. When his daughter Jeryl Lynn Hilleman contracted Mumps Dr. Hilleman cultured the vaccine strain from her throat. The mumps virus strains were developed in embryonic hens' eggs and chick embryo cell cultures. The resulting strains of virus were less well-suited for human cells, and are thus said to be attenuated. They are sometimes referred to as neuroattenuated in the sense that these strains are less virulent to human neurons than the wild strains. The cells used in culture, virus stocks used, and animal fluids are all screened for extraneous material as part of the vaccine production.
Method for measuring virus titer of live attenuated measles, mumps, rubella and varicella combined vaccine
PCT designated stageWO2026008022A1Microbiological testing/measurementMicroorganism based processesChickenpoxTiter
Provided are a primer-probe combination for real-time quantitative PCR, a related kit, and a method for using primers to measure the titers of measles, mumps and varicella virus pathogens. The method is applicable to clinical and laboratory detection, is fast and convenient, and has high sensitivity.
Owner:SHANGHAI INST OF BIOLOGICAL PROD CO LTD
Immunoglobulin G (IgG) antibody of parotitis virus, recombinant IgM antibody and application
The invention relates to the field of in-vitro immunodiagnosis detection, in particular to an IgG antibody of mumps virus, a recombinant IgM antibody and application. Wherein the IgG antibody comprises a heavy chain constant region, a light chain constant region, and a heavy chain variable region and a light chain variable region of the IgG monoclonal antibody which is specifically combined with the mumps virus, and the IgG monoclonal antibody is of a mouse source or a rabbit source. According to the present invention, the IgG antibody is modified to obtain the recombinant IgM antibody, and the IgG antibody and the recombinant IgM antibody are not only suitable for the chemiluminescence method, but also show the expected sensitivity amplification factor in other immunological detection methods, such that the low-abundance detection of the specifically bound mumps virus can be easily achieved.
Owner:INNOVITA BIOLOGICAL TECH CO LTD +1
Viral vectors
The present disclosure provides a cohort of novel viral genome derived products for use, for example, in medicine, as a medicaments, as expression vectors and as adjuvants. The disclosed viral genome derived products may be derived from members of the Paramyxoviridae Family which contains a wide variety of vertebrate viruses, including mumps, measles and human parainfluenza viruses.
Owner:CITY UNIV OF LONDON +1
F-genotype mumps virus attenuated strain and construction method therefor and application thereof
Provided are an F-genotype mumps virus attenuated strain, a construction method therefor and an application thereof. The attenuated strain is a mumps virus with the accession number of CCTCC NO: V201950. Further provided are a vaccine composition containing the F-genotype mumps virus attenuated strain as an active ingredient and a preparation method thereof.
Owner:SHANGHAI KING CELL BIOTECHNOLOGY CO LTD +1
Primer group for detecting mumps virus, application of primer group, kit and application of kit
PendingCN121137263AMicrobiological testing/measurementDNA/RNA fragmentationMultiplexChemical synthesis
The invention relates to the technical field of chemical synthesis and diagnostic reagents, in particular to a primer group for detecting mumps virus, application of the primer group, a kit and application of the kit. The mumps virus NCRs multiplex RT-PCR amplification method is established on the basis of a multiplex PCR principle, one tube for three detections is realized, amplification products of three non-coding regions of N-P, P-M and M-F are obtained through successful amplification, and a full-length sequence of the NCRs is obtained through sequence splicing. Based on the primer group, the invention provides the primer group for detecting the mumps virus NCRs. A gene sequence of mumps virus NCRs is analyzed by a bioinformatics method, and three groups of primers respectively aiming at three non-coding regions of N-P, P-M and M-F are synthesized by a chemical synthesis technology. The primer group provided by the invention can be used for identifying the MuV, can also be used for simultaneously detecting three non-coding region sequences of N-P, P-M and M-F of the MuV, and is used for molecular virology monitoring.
Owner:STATION OF VIRUS PREVENTION & CONTROL CHINA DISEASES PREVENTION & CONTROL CENT
Mumps and measles virus immunogens and their use
ActiveUS12636360B2SsRNA viruses negative-senseAntibody mimetics/scaffoldsMeasles virus IgGChimera Protein
Embodiments of immunogens comprising a recombinant Mumps (MuV) F ectodomain trimer stabilized in a prefusion conformation or a recombinant Measles (MeV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also provided are embodiments of immunogens comprising chimeric proteins comprising the recombinant MuV or MeV F ectodomain trimer and one or more MuV HN or MeV H ectodomains. Also disclosed are nucleic acids encoding the immunogens and methods of their production. Methods for inducing an immune response in a subject by administering a disclosed immunogen to the subject are also provided. In some embodiments, the immune response treats or inhibits MuV and / or MeV infection in a subject.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
Gallid alphaherpesvirus 3 (MDV-2), a viral vector against different avian pathogens: a new vaccination strategy in the poultry industry
The present invention refers in general to the field of veterinary medicine and especially to the development of vectored vaccines using the Gallid alphaherpesvirus 3 (GaHV-3) or Marek's disease serotype 2 (MDV-2) vector, which contains protective antigens against different avian pathogens such as Newcastle disease virus (NDV), avian infectious laryngotracheitis virus (ILTV), infectious bursal disease virus (IBDV) or Gumboro disease virus, avian influenza virus (AIV), infectious bronchitis virus (IBV).
Owner:FARMACOLOGICOS VETERINARIOS S A C
A kit for detecting the pathogen of turtle mumps disease and its usage method
PendingCN122081455Amild dispersionPromote microsphere enrichmentSilicaMicrobiological testing/measurementDiseaseMicrosphere
This invention provides a kit for detecting the pathogen of turtle mumps disease and its usage method, belonging to the field of biodetection technology. The kit includes a tissue pathogen release buffer, magnetic macroporous SiO2 microspheres, nucleic acid extraction solution, and detection reagents for the turtle mumps disease pathogen. This invention uses the tissue pathogen release buffer to release pathogens from tissues, magnetic macroporous SiO2 microspheres for pathogen enrichment, and nucleic acid extraction reagents to obtain a crude extract that can be directly used for LAMP amplification and qPCR amplification detection.
Owner:SHAANXI NORMAL UNIV
Traditional Chinese medicine formula for treating epidemic parotitis and preparation method
The invention provides a traditional Chinese medicine formula for treating epidemic parotitis and a preparation method. The traditional Chinese medicine formula comprises 6-12 parts of radix bupleuri, 9-15 parts of radix scutellariae, 9-15 parts of fructus forsythiae, 9-15 parts of spica prunellae, 9-15 parts of stiff silkworm, 15-30 parts of raw oyster shell, 9-15 parts of flos chrysanthemi indici, 4-9 parts of rhizoma pinellinae praeparata, 9-15 parts of bulbus fritillariae thunbergii and 6-12 parts of raw liquorice root. The traditional Chinese medicine formula is subjected to powdering, soaking, decocting and paste collecting treatment to prepare the paste, a patient can orally take the paste while smearing the paste on the swelling and pain of parotitis during use, and the medicine components can quickly act on the affected part in a mode of combining oral administration and external application, so that the treatment time is effectively shortened, and the treatment effect is improved. The pain of the patient is relieved. In addition, various medicinal materials in the traditional Chinese medicine formula have a synergistic effect, so that the traditional Chinese medicine formula can dredge Shaoyang, clear away heat and toxic materials, remove stasis and subdue swelling, fundamentally treat epidemic parotitis and improve the treatment effect.
Owner:CHONGQING RONGCHANG DISTRICT HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Method for manufacturing viral vaccines and compositions thereof
Present invention provides a method of producing clarified virus pool of virus to obtain a lyophilized / freeze-dried live attenuated virus immunogenic composition / formulation comprising atleast one or more than one antigens / immunogens. Present invention provides a method of producing a clarified virus pool of viruses such as measles, mumps, rubella. It provides the improved large scale affordable / safe manufacturing processes (encompassing cultivation, purification & formulation stages) that utilize minimum animal origin components, provide high virus yield, ensure virus integrity / stability preservation across manufacturing & storage.
Owner:SERUM INST OF INDIA PTE LTD
Application of ABHD12 inhibitor in inhibiting and killing viruses
The invention belongs to the technical field of medicines, and discloses application of an ABHD12 inhibitor in inhibiting and killing viruses. The inventor finds that ABHD12 is a potential broad-spectrum antiviral target through experiments, an inhibitor (such as DO264 or a derivative thereof) of ABHD12 can effectively inhibit proliferation of viruses (such as Zika virus, mumps virus, coronavirus and the like), and the ABHD12 has very good application prospects and research values in the field of antiviral medicines.
Owner:CHINESE INSTITUTES FOR MEDICAL RESEARCH BEIJING
Application of fumaric acid protoicellamate in preparation of medicine for preventing and treating virus infectious diseases
The invention belongs to the technical field of medicines, and discloses application of fumaric acid protoicellamate in preparation of medicines for preventing and treating respiratory virus infectious diseases. The invention particularly relates to application of a natural product fumaric acid protoicellamate or a metabolite thereof in vivo as an active ingredient in preparation of drugs with broad-spectrum antiviral activity and prevention and treatment of virus infectious diseases. The invention also discloses a medicine taking the trans-butene protoicellamate or the analogue thereof as an active ingredient. The traditional Chinese medicine composition can be used for preventing and treating respiratory virus infection such as human respiratory syncytial virus (RSV), human metapneumovirus (HMPV), human rhinovirus (HRV), influenza virus, coronavirus, parainfluenza virus, measles virus, parotitis virus, rubella virus, adenovirus, cytomegalovirus, enterovirus, herpes simplex virus, varicella-zoster virus and the like; and infection of enteroviruses such as coxsackie virus, echovirus and the like can be prevented and treated, and a new drug treatment scheme is provided for clinical viral infection.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Recombinant Non-Pathogenic Marek's Disease Virus Constructs Encoding Infectious Laryngotracheitis Virus and Infectious Bursal Disease Virus Antigens
PendingUS20260021176A1Viral antigen ingredientsAntiviralsInfectious bursal disease virus IBDVLaryngotracheitis virus
The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus protein antigens and an Infectious Bursal Disease virus protein antigen, and methods of their use in poultry vaccines.
Owner:INTERVET INC
Methods for preparing viral vaccines and compositions thereof
The present invention provides methods of producing clarified virus pools to obtain lyophilized / lyophilized live attenuated viral immunogenic compositions / formulations comprising at least one or more than one antigen / immunogen. The invention provides a method for producing clarified virus pools for viruses such as measles, parotitis, rubella and the like. The present invention provides an improved large-scale, burdenable / safe preparation process (encompassing culture, purification and formulation stages) that utilizes minimal animal-derived components, provides high viral yields, and ensures that the viruses maintain integrity / stability during preparation and storage.
Owner:SERUM INST OF INDIA PTE LTD
Immunogens of mumps virus and measles virus and their use
PendingJP2026062907ASsRNA viruses negative-senseAntibody mimetics/scaffoldsNucleotideMeasles virus IgG
The present invention provides polypeptides, polynucleotides, and the like for inducing and detecting immune responses to mumps virus (MuV) and measles virus (MeV). [Solution] An embodiment of an immunogen is provided comprising a MuV F ectodomain trimer or a MeV F ectodomain trimer stabilized in a pre-fusion conformation. Also provided is an embodiment of an immunogen comprising a chimeric protein comprising the recombinant MuV or MeV F ectodomain trimer and one or more MuV HN or MeV H ectodomains. Also disclosed are nucleic acids encoding the immunogen and methods for producing them. Methods for inducing an immune response in a subject by administering the immunogen of this disclosure are also provided. In some embodiments, the immune response treats or inhibits MuV infection and / or MeV infection in the subject.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
Aminobenzoic acid derivatives, pharmaceutically acceptable salts, antiviral drugs and uses
The present application relates to an aminobenzoic acid derivative, a pharmaceutically acceptable salt, an antiviral drug and its application, which has the following general formula structure: wherein R1 is H or an alkali metal atom, R2 is H or an alkali metal atom, and R3 is a halogen atom. The present application designs an aminobenzoic acid derivative with the host Scd1 as a specific target. Through antiviral detection, it is found that the small molecule compound has a significant inhibitory effect on foot-and-mouth disease virus, parainfluenza virus, rubella virus, coxsackie virus, mumps virus and adenovirus, and has no obvious toxic effect on the host cells BHK‑21, LLC‑MK2 and A549 corresponding to foot-and-mouth disease virus, parainfluenza virus, rubella virus, coxsackie virus, mumps virus and adenovirus. The present application proves that the Scd1-specific aminobenzoic acid derivative has good antiviral activity and can be developed and applied as an antiviral drug, which opens up new ideas for the exploration of antiviral drugs.
Owner:WUHAN UNIV
Mumps virus and measles virus immunogens and their uses
ActiveJP7801221B2SsRNA viruses negative-senseOrganic active ingredientsMeasles virus IgGBiomedical engineering
Immunogen embodiments are provided that include a recombinant mumps (MuV) F ectodomain trimer stabilized in a prefusion conformation or a recombinant measles (MeV) F ectodomain trimer stabilized in a prefusion conformation. Also provided are immunogen embodiments that include a chimeric protein comprising the recombinant MuV or MeV F ectodomain trimer and one or more MuV HN or MeV H ectodomains. Nucleic acids encoding the immunogens and methods for their production are also disclosed. Methods for inducing an immune response in a subject by administering an immunogen of the present disclosure to the subject are also provided. In some embodiments, the immune response treats or inhibits MuV and / or MeV infection in the subject. TIFF2023506170000066.tif98128
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
Genotype F mumps attenuated live vaccine production configuration device
PendingCN120519267ABioreactor/fermenter combinationsBiological substance pretreatmentsVaccine ProductionGenotype
The invention discloses a genotype F mumps attenuated live vaccine production configuration, which belongs to the related technical field of vaccine production, and comprises a bracket, a premix unit and a configuration unit, the support has corresponding supporting force, and a supporting table is arranged on one side of the top end of the support and used for supporting the premixing unit. The premixing unit is configured on the supporting table, is communicated with the configuration unit through a connecting structure, and can inject a premix into the configuration unit; the preparation unit is arranged on the support and provided with a preparation shell, the preparation shell comprises an interlayer on the outer side and an inner layer on the inner side of the interlayer, the connecting unit is communicated with the inner layer, and an annular liquid distributor is arranged at the bottom of the inner layer and used for distributing liquid from the bottom. The virus liquid is uniformly distributed into the mixing shell as much as possible and is stirred at different distances through the long blades and the short blades of the stirrer, so that a stirring vortex is formed, and the stirring uniformity is improved.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Large-scale preparation method of parotitis virus with low serum residue
PendingCN120272440ASsRNA viruses negative-senseViral antigen ingredientsGenotypeAttenuated Live Vaccine
The invention relates to the technical field of biology, in particular to a large-scale preparation method of mumps viruses with low serum residues. The method specifically comprises the following steps: digesting resuscitated human diploid cells by using protease, and sequentially culturing in a cell culture solution 01, a cell culture solution 02 and a cell culture solution 03; placing the mumps virus seed in the human diploid cell obtained by culturing, and then placing the human diploid cell in a virus maintenance solution for culturing, so as to obtain a collected supernatant, namely a virus harvesting solution. By optimizing the production process, the pollution risk in the production process is remarkably reduced, the working time is greatly shortened, the overall working efficiency is effectively improved, resource utilization is more efficient, meanwhile, bovine serum residues of the genotype F mumps attenuated live vaccine are reduced, and the production cost is reduced. The potential risk of the bovine serum is avoided; meanwhile, the titer of the cultured virus is not influenced.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Measles-mumps-rubella (MMR) vaccines
PCT designated stageWO2026013289A1SsRNA viruses negative-senseSsRNA viruses positive-senseAntigenMeasles virus IgG
The application generally relates to recombinant genetic constructs comprising a recombinant measles virus expressing at least one rubella virus polypeptide, protein, antigen, or antigenic fragment thereof, and one mumps virus polypeptide, protein, antigen, or antigenic fragment. The application also relates to the uses of genetic constructs or viruses, and more particularly their applications for inducing immune responses and protection against rubella infection, mumps infection, and measles infection.
Owner:INST PASTEUR +1